<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35415942</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1582-4934</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of cellular and molecular medicine</Title>
          <ISOAbbreviation>J Cell Mol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effect of Glut-1 and HIF-1α double knockout by CRISPR/CAS9 on radiosensitivity in laryngeal carcinoma via the PI3K/Akt/mTOR pathway.</ArticleTitle>
        <Pagination>
          <StartPage>2881</StartPage>
          <EndPage>2894</EndPage>
          <MedlinePgn>2881-2894</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jcmm.17303</ELocationID>
        <Abstract>
          <AbstractText>Hypoxic resistance is the main obstacle to radiotherapy for laryngeal carcinoma. Our previous study indicated that hypoxia-inducible factor 1α (HIF-1α) and glucose transporter 1 (Glut-1) double knockout reduced tumour biological behaviour in laryngeal carcinoma cells. However, their radioresistance mechanism remains unclear. In this study, cell viability was determined by CCK8 assay. Glucose uptake capability was evaluated by measurement of <sup>18</sup> F-fluorodeoxyglucose radioactivity. A tumour xenograft model was established by subcutaneous injection of Tu212 cells. Tumour histopathology was determined by haematoxylin and eosin staining, immunohistochemical staining, and TUNEL assays. Signalling transduction was evaluated by Western blotting. We found that hypoxia induced radioresistance in Tu212 cells accompanied by increased glucose uptake capability and activation of the PI3K/Akt/mTOR pathway. Inhibition of PI3K/Akt/mTOR activity abolished hypoxia-induced radioresistance and glucose absorption. Mechanistic analysis revealed that hypoxia promoted higher expressions of HIF-1α and Glut-1. Moreover, the PI3K/Akt/mTOR pathway was a positive mediator of HIF-1α and/or Glut-1 in the presence of irradiation. HIF-1α and/or Glut-1 knockout significantly reduced cell viability, glucose uptake and PI3K/Akt/mTOR activity, all of which were induced by hypoxia in the presence of irradiation. In vivo analysis showed that knockout of HIF-1α and/or Glut-1 also inhibited tumour growth by promoting cell apoptosis, more robustly compared with the PI3K inhibitor wortmannin, particularly in tumours with knockout of both HIF-1α and Glut-1. HIF-1α and/or Glut-1 knockout also abrogated PI3K/Akt/mTOR signalling transduction in tumour tissues, in a manner similar to wortmannin. HIF-1α and/or Glut-1 knockout facilitated radiosensitivity in laryngeal carcinoma Tu212 cells by regulation of the PI3K/Akt/mTOR pathway.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bao</LastName>
            <ForeName>Yang-Yang</ForeName>
            <Initials>YY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Jiang-Tao</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Li-Fang</ForeName>
            <Initials>LF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Li-Bo</ForeName>
            <Initials>LB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Shui-Hong</ForeName>
            <Initials>SH</Initials>
            <Identifier Source="ORCID">0000-0002-7163-2289</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Hong-Tian</ForeName>
            <Initials>HT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Zhong-Jie</ForeName>
            <Initials>ZJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiotherapy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Cell Mol Med</MedlineTA>
        <NlmUniqueID>101083777</NlmUniqueID>
        <ISSNLinking>1582-1838</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051272">Glucose Transporter Type 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495677">SLC2A1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>XVA4O219QW</RegistryNumber>
          <NameOfSubstance UI="D000077191">Wortmannin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064113" MajorTopicYN="N">CRISPR-Cas Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002277" MajorTopicYN="Y">Carcinoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051272" MajorTopicYN="Y">Glucose Transporter Type 1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051795" MajorTopicYN="Y">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007822" MajorTopicYN="Y">Laryngeal Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011836" MajorTopicYN="N">Radiation Tolerance</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077191" MajorTopicYN="N">Wortmannin</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Glut-1</Keyword>
        <Keyword MajorTopicYN="N">HIF-1α</Keyword>
        <Keyword MajorTopicYN="N">PI3K/Akt/mTOR pathway</Keyword>
        <Keyword MajorTopicYN="N">hypoxic radioresistance</Keyword>
        <Keyword MajorTopicYN="N">laryngeal carcinoma</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>5</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35415942</ArticleId>
        <ArticleId IdType="doi">10.1111/jcmm.17303</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Anschuetz L, Shelan M, Dematté M, Schubert AD, Giger R, Elicin O. Long-term functional outcome after laryngeal cancer treatment. Radiat Oncol. 2019;14:101.</Citation>
        </Reference>
        <Reference>
          <Citation>Iizuka Y, Yoshimura M, Inokuchi H, et al. Recurrence patterns after postoperative radiotherapy for squamous cell carcinoma of the pharynx and larynx. Acta Oto-Laryngol. 2015;135:96-102.</Citation>
        </Reference>
        <Reference>
          <Citation>Qureishi A, Rieunier G, Shah KA, et al. Radioresistant laryngeal cancers upregulate type 1 IGF receptor and exhibit increased cellular dependence on IGF and EGF signalling. Clin Otolaryngol. 2019;44:1026-1036.</Citation>
        </Reference>
        <Reference>
          <Citation>Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metast Rev. 2007;26:225-239.</Citation>
        </Reference>
        <Reference>
          <Citation>Palazon A, Goldrath AW, Nizet V, Johnson RS. HIF Transcription Factors, Inflammation, and Immunity. Immunity. 2014;41:518-528.</Citation>
        </Reference>
        <Reference>
          <Citation>Wu FX, Gao HY, Liu KG, et al. The IncRNA ZEB2-AS1 is upregulated in gastric cancer and affects cell proliferation and invasion via miR-143-5p/HIF-1 alpha axis. Oncotargets Ther. 2019;12:657-667.</Citation>
        </Reference>
        <Reference>
          <Citation>Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352:175-180.</Citation>
        </Reference>
        <Reference>
          <Citation>Klaus A, Fathi O, Tatjana TW, Bruno N, Oskar K. Expression of hypoxia-associated protein HIF-1 alpha in follicular thyroid cancer is associated with distant metastasis. Pathol Oncol Res. 2018;24:289-296.</Citation>
        </Reference>
        <Reference>
          <Citation>Hu Y, E H, Yu X, et al. Correlation of quantitative parameters of magnetic resonance perfusion-weighted imaging with vascular endothelial growth factor, microvessel density and hypoxia-inducible factor-1 alpha in nasopharyngeal carcinoma: evaluation on radiosensitivity study. Clin Otolaryngol. 2018;43:425-433.</Citation>
        </Reference>
        <Reference>
          <Citation>Shen LF, Zhao X, Zhou SH, et al. In vivo evaluation of the effects of simultaneous inhibition of GLUT-1 and HIF-1alpha by antisense oligodeoxynucleotides on the radiosensitivity of laryngeal carcinoma using micro 18F-FDG PET/CT. Oncotarget. 2017;8:34709-34726.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang D, Qin Q, Jiang QJ, Wang DF. Bortezomib sensitizes esophageal squamous cancer cells to radiotherapy by suppressing the expression of HIF-1alpha and apoptosis proteins. J Xray Sci Technol. 2016;24:639-646.</Citation>
        </Reference>
        <Reference>
          <Citation>Hennessey D, Martin LM, Atzberger A, Lynch TH, Hollywood D, Marignol L. Exposure to hypoxia following irradiation increases radioresistance in prostate cancer cells. Urol Oncol-Semin Ori. 2013;31:1106-1116.</Citation>
        </Reference>
        <Reference>
          <Citation>Staab A, Fleischer M, Loeffler J, et al. Small interfering RNA targeting HIF-1 alpha reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro. Strahlenther Onkol. 2011;187:252-259.</Citation>
        </Reference>
        <Reference>
          <Citation>Wu XH, Chen SP, Mao JY, Ji XX, Yao HT, Zhou SH. Expression and significance of hypoxia-inducible factor-1 alpha and glucose transporter-1 in laryngeal carcinoma. Oncol Lett. 2013;5:261-266.</Citation>
        </Reference>
        <Reference>
          <Citation>Moon SY, Chang HW, Roh JL, et al. Using YC-1 to overcome the radioresistance of hypoxic cancer cells. Oral Oncol. 2009;45:915-919.</Citation>
        </Reference>
        <Reference>
          <Citation>Sormendi S, Wielockx B. Hypoxia pathway proteins as central mediators of metabolism in the tumor cells and their microenvironment. Front Immunol. 2018;9:40.</Citation>
        </Reference>
        <Reference>
          <Citation>Melstrom LG, Salabat MR, Ding XZ, et al. Apigenin down-regulates the hypoxia response genes: HIF-1alpha, GLUT-1, and VEGF in human pancreatic cancer cells. J Surg Res. 2011;167:173-181.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen J, Cui BM, Fan YP, et al. Protein kinase D1 regulates hypoxic metabolism through HIF-1 and glycolytic enzymes incancer cells. Oncol Rep. 2018;40:1073-1082.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang TB, Zhao Y, Tong ZX, Guan YF. Inhibition of glucose-transporter 1 (GLUT-1) expression reversed Warburg effect in gastric cancer cell MKN45. Int J Clin Exp Med. 2015;8:2423-2428.</Citation>
        </Reference>
        <Reference>
          <Citation>Luo XM, Xu B, Zhou ML, et al. Co-inhibition of GLUT-1 expression and the PI3K/Akt signaling pathway to enhance the radiosensitivity of laryngeal carcinoma xenografts in vivo. PLoS One. 2015;10:e0143306.</Citation>
        </Reference>
        <Reference>
          <Citation>Bao YY, Zhou SH, Lu ZJ, Fan J, Huang YP. Inhibiting GLUT-1 expression and PI3K/Akt signaling using apigenin improves the radiosensitivity of laryngeal carcinoma in vivo. Oncol Rep. 2015;34:1805-1814.</Citation>
        </Reference>
        <Reference>
          <Citation>Yan SX, Luo XM, Zhou SH, et al. Effect of antisense oligodeoxynucleotides glucose transporter-1 on enhancement of radiosensitivity of laryngeal carcinoma. Int J Med Sci. 2013;10:1375-1386.</Citation>
        </Reference>
        <Reference>
          <Citation>Lu ZJ, Yu Q, Zhou SH, et al. Construction of a GLUT-1 and HIF-1 alpha gene knockout cell model in HEp-2 cells using the CRISPR/Cas9 technique. Cancer Manag Res. 2019;11:2087-2096.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang G, Li J, Wang X, et al. The reverse Warburg effect and 18F-FDG uptake in non-small cell lung cancer A549 in mice: a pilot study. J Nucl Med. 2015;56:607-612.</Citation>
        </Reference>
        <Reference>
          <Citation>Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging. 2008;35:2294-2303.</Citation>
        </Reference>
        <Reference>
          <Citation>Busk M, Horsman MR, Kristjansen PE, van der Kogel AJ, Bussink J, Overgaard J. Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer. 2008;122:2726-2734.</Citation>
        </Reference>
        <Reference>
          <Citation>Jiang T, Zhou ML, Fan J. Inhibition of GLUT-1 expression and the PI3K/Akt pathway to enhance the chemosensitivity of laryngeal carcinoma cells in vitro. Onco Targets Ther. 2018;11:7865-7872.</Citation>
        </Reference>
        <Reference>
          <Citation>Xu YY, Wu TT, Zhou SH, et al. Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study. Int J Clin Exp Patho. 2014;7:3938-3947.</Citation>
        </Reference>
        <Reference>
          <Citation>Hamilton DW, Pedersen A, Blanchford H, et al. A comparison of attitudes to laryngeal cancer treatment outcomes: a time trade-off study. Clin Otolaryngol. 2018;43:117-1123.</Citation>
        </Reference>
        <Reference>
          <Citation>Mayer A, Schneider F, Vaupel P, Sommer C, Schmidberger H. Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma. Int J Oncol. 2012;41:1260-1270.</Citation>
        </Reference>
        <Reference>
          <Citation>Swartz JE, Pothen AJ, van Kempen PMW, et al. Poor prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinomas that overexpress hypoxia inducible factor-1 alpha. Head Neck. 2016;38:1338-1346.</Citation>
        </Reference>
        <Reference>
          <Citation>Dai LB, Yu Q, Zhou SH, et al. Effect of combination of curcumin and GLUT-1 AS-ODN on radiosensitivity of laryngeal carcinoma through regulating autophagy. Head Neck. 2020;42:2287-2297.</Citation>
        </Reference>
        <Reference>
          <Citation>Dai LB, Zhong JT, Shen LF, et al. Radiosensitizing effects of curcumin alone or combined with GLUT1 siRNA on laryngeal carcinoma cells through AMPK pathway-induced autophagy. J Cell Mol Med. 25(13):6018-6031.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhu GC, Peng FS, Gong W, et al. Hypoxia promotes migration/invasion and glycolysis in head and neck squamous cell carcinoma via an HIF-1 alpha-MTDH loop. Oncol Rep. 2017;38:2893-2900.</Citation>
        </Reference>
        <Reference>
          <Citation>Leung E, Cairns RA, Chaudary N, et al. Metabolic targeting of HIF-dependent glycolysis reduces lactate, increases oxygen consumption and enhances response to high-dose single-fraction radiotherapy in hypoxic solid tumors. BMC Cancer. 2017;17:418.</Citation>
        </Reference>
        <Reference>
          <Citation>Zornhagen KW, Hansen AE, Oxboel J, et al. Micro regional heterogeneity of Cu-64-ATSM and F-18-FDG uptake in canine soft tissue sarcomas: relation to cell proliferation, hypoxia and glycolysis. PLoS One. 2015;10:e0141379.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang H, Zhao L, Zhu LT, et al. Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1 alpha and glycolysis, by inhibiting PI3K/Akt signaling pathway. Mol Carcinogen. 2014;53:E107-E118.</Citation>
        </Reference>
        <Reference>
          <Citation>Xie Y, Shi X, Sheng K, et al. PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review). Mol Med Rep. 2019;19:783-791.</Citation>
        </Reference>
        <Reference>
          <Citation>Tamburini J, Chapuis N, Bardet V, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood. 2008;111:379-382.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen G, Yuan C, Duan F, et al. IGF1/MAPK/ERK signaling pathway-mediated programming alterations of adrenalcortex cell proliferation by prenatal caffeine exposure in male offspring rats. Toxicol Appl Pharmacol. 2018;341:64-76.</Citation>
        </Reference>
        <Reference>
          <Citation>Lu J, Tan M, Cai Q. The Warburg effect in tumor progression: Mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett. 2015;356:156-164.</Citation>
        </Reference>
        <Reference>
          <Citation>Markowska J, Grabowski JP, Tomaszewska K,. et al. Significance of hypoxia in uterine cervical cancer. Multicentre study. Eur J Gynaecol Oncol. 2007;28:386-388.</Citation>
        </Reference>
        <Reference>
          <Citation>Basavaraju AM, Shivanna N, Yadavalli C, Garlapati PK, Raghavan AK. Ameliorative effect of ananas comosus on cobalt chloride-induced hypoxia in Caco2 cells via HIF-1alpha, GLUT 1, VEGF, ANG and FGF. Biol Trace Elem Res. 2021;199:1345-1355.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
